JP2013507371A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013507371A5 JP2013507371A5 JP2012533272A JP2012533272A JP2013507371A5 JP 2013507371 A5 JP2013507371 A5 JP 2013507371A5 JP 2012533272 A JP2012533272 A JP 2012533272A JP 2012533272 A JP2012533272 A JP 2012533272A JP 2013507371 A5 JP2013507371 A5 JP 2013507371A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- halo
- phenyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000001475 halogen functional group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 208000006888 Agnosia Diseases 0.000 claims 2
- 241001047040 Agnosia Species 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims 1
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004858 cycloalkoxyalkyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005059 halophenyl group Chemical group 0.000 claims 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 0 CCCc(cc1)ccc1-c(cc1)ccc1N(C[C@@](*)[C@@](C)CC)C([C@](CC)(C1)C1c1ncccc1)=O Chemical compound CCCc(cc1)ccc1-c(cc1)ccc1N(C[C@@](*)[C@@](C)CC)C([C@](CC)(C1)C1c1ncccc1)=O 0.000 description 5
- RXWOORQHRSXVQF-RNXOBYDBSA-N CCC[C@@H](CN(C([C@@H](C1)[C@H]1c1nc(F)ccc1)=O)c(cc1)ccc1-c1ccc(CCC)cc1)N Chemical compound CCC[C@@H](CN(C([C@@H](C1)[C@H]1c1nc(F)ccc1)=O)c(cc1)ccc1-c1ccc(CCC)cc1)N RXWOORQHRSXVQF-RNXOBYDBSA-N 0.000 description 1
- KQXKPVZKWPSUPC-UHFFFAOYSA-N Fc1cccc(C2CC2)n1 Chemical compound Fc1cccc(C2CC2)n1 KQXKPVZKWPSUPC-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25009109P | 2009-10-09 | 2009-10-09 | |
| US61/250,091 | 2009-10-09 | ||
| PCT/US2010/051597 WO2011044212A1 (en) | 2009-10-09 | 2010-10-06 | Modulators of g protein-coupled receptor 88 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013507371A JP2013507371A (ja) | 2013-03-04 |
| JP2013507371A5 true JP2013507371A5 (enExample) | 2013-11-21 |
Family
ID=43479451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012533272A Pending JP2013507371A (ja) | 2009-10-09 | 2010-10-06 | Ｇタンパク質共役受容体８８の調節因子 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8426414B2 (enExample) |
| EP (1) | EP2486014B1 (enExample) |
| JP (1) | JP2013507371A (enExample) |
| CN (1) | CN102648180A (enExample) |
| ES (1) | ES2430946T3 (enExample) |
| WO (1) | WO2011044212A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8497271B2 (en) | 2009-10-07 | 2013-07-30 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| US8304577B2 (en) | 2009-10-09 | 2012-11-06 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| US8703953B2 (en) | 2012-03-09 | 2014-04-22 | Bristol-Myers Squibb Company | Aryl ether-base kinase inhibitors |
| WO2015006100A1 (en) | 2013-07-08 | 2015-01-15 | Bristol-Myers Squibb Company | Aryl amide kinase inhibitors |
| CN105979950A (zh) | 2013-10-11 | 2016-09-28 | 百时美施贵宝公司 | 吡咯并三嗪激酶抑制剂 |
| MX2020009950A (es) | 2018-03-23 | 2021-04-28 | Carmot Therapeutics Inc | Moduladores de receptores acoplados a proteina g. |
| JP2023550643A (ja) * | 2020-11-25 | 2023-12-04 | レネオ ファーマシューティカルズ，インク． | Ｐｐａｒデルタアゴニストの製造方法 |
| US20240132450A1 (en) | 2020-12-17 | 2024-04-25 | Acadia Pharmaceuticals Inc. | Modulators of g protein-coupled receptor 88 |
| KR20240007251A (ko) | 2021-05-13 | 2024-01-16 | 카모트 테라퓨틱스, 인크. | G-단백질 결합 수용체의 조절제 |
| GB202209193D0 (en) | 2022-06-22 | 2022-08-10 | Pandeia Therapeutics Ltd | Modulators of g protein-coupled receptor 88 |
| GB202209195D0 (en) | 2022-06-22 | 2022-08-10 | Pandeia Therapeutics Ltd | Modulators of g protein-coupled receptor 88 |
| WO2026055419A1 (en) | 2024-09-05 | 2026-03-12 | Acadia Pharmaceuticals Inc. | Modulators of g protein-coupled receptor 88 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0672031T3 (da) | 1992-12-02 | 2003-06-10 | Pfizer | Catecholdiethere som selektive PDE IV-inhibitorer |
| US5709861A (en) | 1993-04-22 | 1998-01-20 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
| ATE388946T1 (de) | 2002-04-05 | 2008-03-15 | Boehringer Ingelheim Pharma | Cyanamide als reversible hemmer von cystein proteasen |
| WO2003103666A2 (en) | 2002-06-07 | 2003-12-18 | Altana Pharma Ag | Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones |
| EP1565190A4 (en) | 2002-11-22 | 2006-04-26 | Bristol Myers Squibb Co | ARYLCYCLOPROPYLCARBOXYLIC ACID AMIDE AS A KALIUM CHANNEL OPENER |
| WO2004056744A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| EP1593667A4 (en) | 2003-02-12 | 2009-03-04 | Takeda Pharmaceutical | Amine derivative |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| WO2005051890A1 (en) | 2003-11-19 | 2005-06-09 | Smithkline Beecham Corporation | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40 |
| CA2570694A1 (en) | 2004-06-24 | 2006-02-02 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| US20080153917A1 (en) | 2004-09-10 | 2008-06-26 | Ucb Pharma, S.A. | Sigma Receptor Ligands |
| GB0428250D0 (en) * | 2004-12-23 | 2005-01-26 | Novartis Ag | Organic compounds |
| CN100494167C (zh) | 2005-08-02 | 2009-06-03 | 天津大学 | 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用 |
| JP2007217408A (ja) | 2006-01-19 | 2007-08-30 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| JP5420395B2 (ja) | 2006-04-07 | 2014-02-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｐ結合カセット輸送体の調節剤 |
| WO2007129188A1 (en) | 2006-05-10 | 2007-11-15 | Pfizer Japan Inc. | Cyclopropanecarboxamide compound |
| US20080040819A1 (en) | 2006-08-14 | 2008-02-14 | Wyeth | Methods of identifying agents for treatment of schizophrenia and related disorders |
| US8497271B2 (en) | 2009-10-07 | 2013-07-30 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| US8304577B2 (en) | 2009-10-09 | 2012-11-06 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
-
2010
- 2010-10-04 US US12/897,004 patent/US8426414B2/en active Active
- 2010-10-06 EP EP10765716.5A patent/EP2486014B1/en not_active Not-in-force
- 2010-10-06 JP JP2012533272A patent/JP2013507371A/ja active Pending
- 2010-10-06 CN CN2010800560408A patent/CN102648180A/zh active Pending
- 2010-10-06 WO PCT/US2010/051597 patent/WO2011044212A1/en not_active Ceased
- 2010-10-06 ES ES10765716T patent/ES2430946T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013507374A5 (enExample) | ||
| CY1121781T1 (el) | Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης της ρασαγιλινης και χρησεις αυτων | |
| WO2012009258A3 (en) | Peptidomimetic galanin receptor modulators | |
| JP2015501783A5 (enExample) | ||
| JP2016528301A5 (enExample) | ||
| JP2018518537A5 (enExample) | ||
| JP2010505958A5 (enExample) | ||
| JP2013540713A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2014051526A5 (enExample) | ||
| JP2017526677A5 (enExample) | ||
| JP2013519675A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2013056919A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2013507369A5 (enExample) | ||
| JP2015500223A5 (enExample) | ||
| BR112014003225A2 (pt) | profármacos de treprostinil ligados a veículo | |
| JP2016503797A5 (enExample) | ||
| JP2011529054A5 (enExample) | ||
| JP2014508752A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2018537535A5 (enExample) | ||
| JP2019516739A5 (enExample) | ||
| JP2012092103A5 (enExample) |